Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35008514/
doi: 10.3390/ijms23010081. 1 Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia. 2 Department of Pharmacology, Masonic Cancer Center, University of Minnesota, Minneapolis,...
Conclusion/Relevance: Administering anti-PD-1 sequentially after fulvestrant plus dacomitinib was synergistic, with a two-fold greater tumor inhibitory effect compared to concomitant therapy, in both the flank model and in a lung metastasis model. Sequential triple therapy has potential for treating lung cancer that shows limited response to...
Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
Source : https://www.jtocrr.org/article/S2666-3643(21)00120-X/fulltext
Our approach to NSCLC has transformed dramatically with the discovery of numerous therapeutically targetable oncogenic alterations, and notable examples include EGFR, ALK, ROS1, and BRAF. In contrast, oncogenic KRAS mutations...
Conclusions: Whereas treatment outcomes with conventional anticancer therapy are reasonable and immunotherapy looks promising, the unmet need remains high for patients with KRAS-mutated NSCLC in Asia, underscoring the need for novel therapeutic approaches.
Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35011738/
In non-small-cell lung cancer (NSCLC), concurrent mutations in the oncogene KRAS and tumor suppressor STK11 (also known as LKB1) confer an aggressive malignant phenotype, an unfavourability towards immunotherapy, and overall...
Conclusion/Relevance: “Our results define an additional metabolic vulnerability in KRAS/LKB1 co-mutant tumors to the HBP and provide a rationale for targeting PGM3 in this aggressive subtype of NSCLC.”
High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRAS G12C by Intact Protein MS and Targeted MRM - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34990117/
With recent advances and success in several drugs designed to treat acute and chronic diseases, targeted covalent inhibitors show a resurgence in drug discovery. As covalent inhibition is time-dependent, the...
Relevance: Here, we present the development of a mass spectrometry-based platform for rapid kinetic analysis of irreversible covalent inhibitors.
KRAS Mutations in Squamous Cell Carcinomas of the Lung - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34976827/
KRAS is one of the most commonly mutated oncogenes in cancer, enabling tumor proliferation and maintenance. After various approaches to target KRAS have failed over the past decades, the first...
Conclusion/Relevance: In squamous cell carcinoma (SCC) of the lung, KRAS mutations are rare and their impact on clinical outcome is poorly understood. In this review, we discuss the current knowledge on the prevalence and prognostic and predictive significance of KRAS mutations in the context of SCC.